Resources
Big Molecule Watch
- Fresenius Kabi and Formycon Reach Settlement Agreement for Ustekinumab Biosimilar Candidate in Europe and Canada March 28, 2024 Gabriella Montes
- FDA Approves First Gene Therapy to Treat Children with Metachromatic Leukodystrophy March 28, 2024 Lihui Bai
- Biden Administration Proposes Biosimilar Substitution Without Interchangeability March 27, 2024 Seth Manilove
- Women’s History Month Spotlight: Emmanuelle Charpentier and Jennifer Doudna March 22, 2024 Beth Ashbridge
- Celltrion Announces Commercial Availability of ZYMFENTRA™ (infliximab-dyyb) March 19, 2024 Kristin Beale
- Updates on Aflibercept BPCIA Litigation March 19, 2024 Grace Truong
- Celltrion Submits BLA for Omalizumab Biosimilar March 18, 2024 Alison Siedor
- Fresenius Kabi Announces FDA Approval of TYENNE, a Tocilizumab Biosimilar Referencing ACTEMRA March 15, 2024 Sam Herron
- FDA Approves Sandoz Denosumab Biosimilars March 8, 2024 Emma Murray
- Biocon Settles with Bayer and Regeneron, Securing Canada Market Entry Date for Aflibercept Biosimilar March 7, 2024 Emma Murray
BioPharma Reporter
- Lonza expands offering for spray-dried biologics for pulmonary delivery March 28, 2024
- AstraZeneca CEO ‘deeply humbled’ by award recognising pandemic efforts March 28, 2024
- Reshema Kemps-Polanco: No ‘silver bullet’ to address health equity but Novartis making strides March 27, 2024
- Women in Science: Follow your passion and you’ll get to where you’re meant to be - Jennifer Visser-Rogers March 27, 2024
- GSK’s Maya Martinez David: ‘Trust is the most powerful thing in an organization’ March 26, 2024
- New research highlights potential of HIF Inhibition as a therapeutic approach for cancers March 26, 2024
- Teva UK and Closed Loop Medicine partner to bolster personalized medicines March 26, 2024
- Reuters Pharma USA 2024: What are key pharma players hoping to achieve? March 25, 2024
- New wave of potential therapies to bring ‘paradigm shift’ in COPD treatment March 25, 2024
- Claudia Zylberberg on her cell and gene industry triumphs and ISCT hopes March 22, 2024